Synapse
⌘+K
Synapse
PulseExploreClubsResearchersJournals
Instagram
HomeClubsExplore
December 8, 2025Blood

Clinical features and outcomes of myelofibrosis patients with MPL mutations

View Full Paper
Ask AI
Bookmark
Share

Authors

VNValentina NardiAKAndrew Kuykendall

Discussion

Loading...

Member takes

Overview

Retrospective case series reveals high-risk mutations and varied outcomes in myelofibrosis patients with MPL mutations.

Key Points

  • To characterize clinical features and outcomes of myelofibrosis patients with MPL mutations.
  • Retrospective case series at two cancer centers between 2010-2022.
  • Included patients with myelofibrosis and confirmed MPL mutations identified via next-generation sequencing.
  • Data collected on demographics, molecular profiles, treatment history, and clinical outcomes.
  • 73 patients identified with MPL mutations in myelofibrosis.
  • High molecular risk mutations present in over 50% of patients.
  • Significant progression to acute myeloid leukemia observed in 15% of patients.

Cite This Study

Nardi et al. (2025) studied this question.

synapsesocial.com/papers/69362f694fa91c937236df7ahttps://doi.org/10.1182/blood-2025-5601
View Full Paper
Ask AI
Bookmark
Share

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

  1. 1Clinical features and outcomes of myeloproliferative neoplasm patients with MPL mutations and concurrent JAK2/calr mutations2025
  2. 2Molecular characterization and improved risk stratification of myelodysplastic syndromes with bone marrow fibrosis through integration of TP53 and MPL mutations2026
  3. 3Myeloproliferative neoplasm driver mutations (JAK2/CALR/MPL) in chronic myelomonocytic leukemia are associated with an increased risk of blast transformation2025
  4. 4Broad Next-Generation Integrated Sequencing of Myelofibrosis Identifies Disease-Specific and Age-Related Genomic Alterations2024 · 11 citations
  5. 5MPN with multiple driver clones show distinct patterns of therapy response and progression - “MPN double driver”2025 · 2 citations